The Future of ErbB-1 and ErbB-2 Pathway Inhibition in Breast Cancer: Targeting Multiple Receptors

The Future of ErbB-1 and ErbB-2 Pathway Inhibition in Breast Cancer: Targeting Multiple Receptors Guest Editor: Dennis J. Slamon, M.D., Ph.D. Oncologist 2004; 9(Suppl 3): 1-28 Target Audience: Physicians who wish to advance their current knowledge of cancer medicine in Breast Cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional).

• Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition EXPIRED
• The Role of ErbB Inhibitors in Trastuzumab Resistance EXPIRED
• Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbB-2 Inhibitor Lapatinib EXPIRED
• Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer EXPIRED